India Urged to Ban Smoking Zones in Hotels, Restaurants, Airports

Regulations by 2FIRSTS.ai
Mar.14.2024
India Urged to Ban Smoking Zones in Hotels, Restaurants, Airports
Doctors, cancer patients, and hotels are urging the Indian government to ban designated smoking areas in public places.

According to a report by telegraphindia, doctors, cancer patients, and hotels are urging the Indian government to ban designated smoking rooms in hotels, restaurants, and airports in order to protect the public from secondhand smoke.

 

Dr. Harit Chaturvedi, Chair of Cancer Care at Kesar Medical Center, stated: "Smoking exacerbates lung function impairment and lowers immunity. All designated smoking areas in hotels, restaurants, and even airports should be abolished to ensure a completely smoke-free environment. Most designated smoking areas rarely meet the requirements of COTPA, exposing our public to significant health risks due to secondhand smoke inhalation."

 

According to the 2003 Cigarettes and Other Tobacco Products Act (COTPA), smoking is prohibited in all public places. However, smoking is still allowed in designated smoking areas in some public places such as restaurants, hotels, and airports.

 

Health activity expert Nalini Satyanarayan stated, "Passive smoking mostly occurs in restaurants, especially in hotels, eateries, bars, clubs, etc. Cigarette smoke can permeate from smoking zones into public areas. The COTPA needs to be amended to prohibit smoking in any location, as this aligns with the best interests of public health."

 

Currently, the Indian government has initiated the process of amending COTPA and has introduced the 2020 Amendment to the Tobacco Products (Prohibition of Advertisement and Regulation of Trade, Commerce, Production, Supply and Distribution) Act.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | ELFBAR launches new “4-in-1” e-cigarette kit: 4× (1ml + 5ml) design, 4 flavors per set
Product | ELFBAR launches new “4-in-1” e-cigarette kit: 4× (1ml + 5ml) design, 4 flavors per set
ELFBAR has launched the “4 in 1 Ultra 50 VAPE KIT” through multiple online sales channels in the UK. The kit combines four 1ml prefilled pods with four 5ml refill containers. The company claims it can deliver up to around 50,000 puffs, with a retail price of approximately £13.99.
Dec.31 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
U.S. FDA posts TPSAC meeting materials ahead of discussion on ZYN MRTP applications
U.S. FDA posts TPSAC meeting materials ahead of discussion on ZYN MRTP applications
On January 20, 2026, the U.S. Food and Drug Administration (FDA) posted meeting materials ahead of a virtual Tobacco Products Scientific Advisory Committee (TPSAC) meeting scheduled for January 22, 2026, to discuss modified risk tobacco product (MRTP) applications submitted by Swedish Match USA, Inc. for 20 ZYN nicotine pouch products.
Jan.21 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
UK vape firm Plxsur sold for £76,500 after touting $1 billion revenue target
UK vape firm Plxsur sold for £76,500 after touting $1 billion revenue target
London-based vaping company Plxsur, which had claimed in fundraising materials it could reach $1 billion in annual revenue and capture about 10% of the global vaping market, has been sold out of administration for £76,500. Administrators said the figures were aspirational and depended on acquisitions that were never completed, as the company later ran out of cash and entered insolvency, with a shareholder ultimately buying the business.
Jan.22 by 2FIRSTS.ai
PMI says Colorado ZYN plant build advances as first pouches hit market in 2025
PMI says Colorado ZYN plant build advances as first pouches hit market in 2025
Philip Morris International (PMI) is investing $600 million to build a ZYN nicotine pouch plant in Aurora, Colorado. While the facility is still under construction, PMI said production started in September 2025 and the first pouches made at the site have already gone to market.
Feb.10 by 2FIRSTS.ai